Molly DiLullo

Also affiliated with Dana-Farber Brigham Cancer Center

MedicineBiochemistry, Genetics and Molecular BiologyComputer Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer”.

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2024-010430

N/A

0.416DataRank · unranked

15 citations

Noah Graham, Lestat R. Ali, Christina I. Herold, Jennifer Desrosiers, Khanh Do +13 more

Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer

Nature Communications(2025)10.1038/s41467-025-66659-y

N/A

0.165DataRank · unranked

2 citations

Adrienne G. Waks, Erica Pimenta, Breanna Titchen, Kevin Bi, Sabrina Y. Camp +16 more

896 Characterizing macrophage heterogeneity in HR+/HER2- metastatic breast cancer reveals novel mechanisms of resistance

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0896

N/A

0DataRank · unranked

0 citations

Kenichi Shimada, Madeline G Townsend, Tianyu Li, Nabihah Tayob, Molly DiLullo +9 more